Inozyme Pharma

Treatments for PPi-Adenosine Pathway, ENPP1 Deficiency, ABCC6 Deficiency, & calciphylaxis.

Based in MA

🤖

AI Overview

With $20K in lobbying spend across 3 quarterly filings, Inozyme Pharma is an active lobbying client. Their lobbying covers 1 issue area.

$20K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2025	$20K

Issues Lobbied

Pharmacy

Lobbying Firms

The Kpm Group DC LLC

Lobbyists

Jacob Jackson Patroski Lawson Paula Gutierrez Alexander Root

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy

•FDA modernization H.R.1262 - Give Kids a Chance Act Trump administration impact on staffing at HHS and FDA Newborn screening Inflation Reduction Act (IRA) H.R.946 - ORPHAN Cures Act H.R. 1414 - Camero

•H.R.1262/S.932 - Give Kids a Chance Act H.R.946 - ORPHAN Cures Act H.R. 1414 - Cameron's Law H.R.1532/S.822 - Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1492 - En